Healthcare
Genetic Technologies Limited (ASX:GTG)
Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Life Sciences Tools & Services
Market Price : AUD 0.00750 (0%)
(as on 2021-10-24 00:10:38)
| Previous Close | Open | Close* | Day Range | 52 WEEK HIGH LOW |
|---|---|---|---|---|
| 0.0075 | 0.007 | 0.0075 | 0.007L 0.0075 H | 0.006L 0.014 H |
| Last Trade | 0.0075 |
|---|---|
| Change% | 0.0000 |
| 52 W H/L | 0.014/0.006 |
| EBITDA | -7.064 M |
|---|---|
| NPAT After Abnormal Items | -7.078 M |
| Equity | 21.533 M |
| ROE% | -32.87% |
| Total Liabilities | 1.439 M |
|---|---|
| Total Revenue | 1.623 M |
| Cash and Cash Equivalents | 20.902 M |
Stock Information
| Share price | 0.0075 |
|---|---|
| Market Cap | 69.196 M |
| Price/Gross Cash Flow | -16.23 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 9.017 B | 52-Week Range | 0.006-0.014 |
| P/E ratio | 0.000 |
|---|---|
| Sector P/E | -- | EPS | -0.08 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -5,870.91% |
| Gross Cash Flows Per Share | -0.00 |
| Net Gearing | -96.12% |
| Gross DPS (AUD) | 0 |
|---|---|
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 0.000 |
| Net Tangible Asset (NTA) | 0.00 |
| Sales Per Share | 0.00 |
| Book Value Per Share | 0.00 |
Announcements
About Company
Diversified molecular diagnostics company Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) is engaged in developing risk assessment tests based on genetic technology. The Company provides tests to predict an individual’s risk of developing a chronic indication. Genetic Technologies offers predictive testing as well as assessment tools for cancers and other diseases to aid physicians in proactively managing patient health.
GTG is developing a product pipeline of first-in-class, clinically validated risk assessment tests. The diagnostic Company is working to enhance the health outcomes for people across the globe by offering risk assessment tools to develop personalised health management strategies to detect and treat chronic diseases.
The Company continually strives to maintain its position as a global leader in the genomics industry by investing in its research capabilities and collaborations with experts from world-class organisations, including universities, research organisations, and progressive medical product distribution companies.
Genetic Technologies owns and operates a world-class Clinical Laboratory Improvement Amendments (CLIA) authorised laboratory in Melbourne, Australia. The Company has collaborative agreements with other laboratory operators worldwide for ensuring the availability of its world-class genetic tests in selected jurisdictions.
GTG’s lead products include GeneType for Breast Cancer and GeneType for Colorectal Cancer.
GeneType for Breast Cancer (non-hereditary breast cancer)
GeneType for Breast Cancer can determine the risk of a woman developing sporadic breast tumour over a period. Three key factors contributing to the risk of developing sporadic breast cancer include genetic markers, family history, and breast density.
GeneType for Breast Cancer combines all the risk factors to offer a more accurate assessment of the risk of developing breast cancer.
GeneType for Colorectal Cancer
GeneType test for Colorectal Cancer can determine the risk of developing colorectal tumour over a period. The test combines several factors, including the patient’s family history, age, and genetic markers, to provide a more precise assessment of the risk of developing colorectal cancer.
The Company is also developing risk assessment test for type 2 diabetes, cardiovascular indications, prostate cancer, melanoma, and COVID-19.
Corporate Information
|
|
|
|
60-66 Hanover Street, FITZROY, VIC, AUSTRALIA, 3065
(03) 8412 7000
Dividends
| Ex-Dividend Date | Franking | DPS (AUD) | Dividend Yield |
|---|---|---|---|
| 30/06/2021 | -- | 0.000 | 0.00% |
| 30/06/2020 | -- | 0.000 | 0.00% |
| 30/06/2019 | -- | 0.000 | 0.00% |
| 30/06/2018 | -- | 0.000 | 0.00% |
| 30/06/2017 | -- | 0.000 | 0.00% |
| 30/06/2016 | -- | 0.000 | 0.00% |
| 30/06/2015 | -- | 0.000 | 0.00% |
| 30/06/2014 | -- | 0.000 | 0.00% |
| 30/06/2013 | -- | 0.000 | 0.00% |
| 30/06/2012 | -- | 0.000 | 0.00% |
Event Calendar
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Annual) | 2022-08-30 | 2022 |
| Report (Prelim) | 2022-08-30 | 2022 |
| Report (Interim) | 2022-02-25 | 2022 |
Financials
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Trading Revenue | 120,554 | 9,864 | 25,444 | 189,254 | 518,506 |
| Other Revenue | 1.502 M | 1.314 M | 667,792 | 1.082 M | 305,347 |
| Total Revenue | 1.623 M | 1.324 M | 693,236 | 1.271 M | 823,853 |
| Interest Income | 62,394 | 22,507 | 0 | 15,218 | 38,765 |
| Interest Expenses | -14,049 | -14,823 | -20,031 | -28,843 | -31,995 |
| Expenses | -8.483 M | -7.365 M | -6.86 M | -5.89 M | -8.318 M |
| EBITDA | -6.86 M | -6.041 M | -6.167 M | -4.619 M | -7.494 M |
| Depreciation and Amortization | -265,748 | -65,148 | -182,811 | -303,749 | -371,611 |
| Depreciation | -265,748 | -65,148 | -182,811 | -303,749 | -307,828 |
| Amortisation | 0 | 0 | 0 | 0 | -63,783 |
| EBIT | -7.126 M | -6.107 M | -6.35 M | -4.923 M | -7.866 M |
| Pre Tax Profit | -7.078 M | -6.099 M | -6.37 M | -4.937 M | -7.859 M |
| Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Profit After Tax | -7.078 M | -6.099 M | -6.37 M | -4.937 M | -7.859 M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Preference Dividend | 0 | 0 | 0 | 0 | 0 |
| Net Abnormal Items | 0 | 0 | -500,000 | -527,049 | -544,694 |
| Reported Net Profit After Abnormal Items | -7.078 M | -6.099 M | -6.87 M | -5.464 M | -8.404 M |
| Ending Shares | 9.017 B | 7.514 B | 3.148 B | 2.609 B | 2.609 B |
| Weighted Average Shares | 8.544 B | 4.155 B | 2.824 B | 2.609 B | 2.273 B |
| EPS After Abnormal Items (cents) | -0.08 | -0.15 | -0.24 | -0.21 | -0.37 |
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Total Current Assets | 22.236 M | 15.193 M | 2.751 M | 5.991 M | 11.632 M |
| Total Non Current Assets | 735,574 | 440,230 | 69,333 | 175,284 | 476,648 |
| Total Assets | 22.972 M | 15.633 M | 2.821 M | 6.166 M | 12.108 M |
| Total Current Liabilities | 1.405 M | 1.398 M | 1.493 M | 1.451 M | 1.465 M |
| Total Non Current Liabilities | 33,272 | 1.22 M | 809 | 3,390 | 63,960 |
| Total Liabilities | 1.439 M | 2.618 M | 1.494 M | 1.454 M | 1.529 M |
| Net Assets | 21.533 M | 13.015 M | 1.327 M | 4.712 M | 10.579 M |
| Breakdown | 30/06/2021 | 30/06/2020 | 30/06/2019 | 30/06/2018 | 30/06/2017 |
|---|---|---|---|---|---|
| Net Operating Cash | -6.296 M | -5.712 M | -6.521 M | -5.621 M | -6.814 M |
| Net Invested Cash | -748,706 | 64,787 | -76,860 | -2,385 | -182,149 |
| Net Financing Cash Flows | 13.69 M | 18.36 M | 3.126 M | -9,963 | 7.11 M |
| Beginning Cash | 14.214 M | 2.132 M | 5.487 M | 10.988 M | 11.18 M |
| End Cash Position | 20.902 M | 14.214 M | 2.132 M | 5.487 M | 10.988 M |
| Exchange Rate Adjustments | 42,761 | -630,616 | 116,186 | 132,443 | -305,693 |
| Other Cash Adjustments | 0 | 0 | 0 | 0 | 0 |
| Ending Cash | 20.902 M | 14.214 M | 2.132 M | 5.487 M | 10.988 M |
© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.